The Food and Drug Administration this week conditionally approved Aducanumab, the first new approval in nearly two decades.
The Food and Drug Administration this week conditionally approved Aducanumab, the first new approval in nearly two decades.
The new drug targets amyloid, a protein that forms in the brain creating plaques, which are believed to cause dementia.
New medicine made from living cells given by infusion reduces plaque on the brain, gives hope for sufferers.
Melanie Townsend reports